evaluations+economics

Most Americans—79 percent—consider U.S. prescription drug prices to be unreasonable, with almost 3 in 10 reporting they go without prescribed medications because of cost.

Vaccines remain the best way to protect against serious illness. A week after the FDA gave full approval to Pfizer's COVID-19 vaccine, it's not known if that's nudging more people to get the shot.

As the coronavirus pandemic has shown us, there are many disparities in the United States in regards to healthcare coverage.

This year the World Preview focuses on how biopharma companies are navigating this new landscape, and the potential lasting effects of the pandemic.

The data, published in the U.S. Centers for Disease Control and Prevention's weekly report on death and disease, shows an increase in so-called "breakthrough" infections among fully vaccinated individuals.

The study was based on data from more than a million app users, comparing self-reported infections in vaccinated participants with cases in an unvaccinated control group.

The study, known as HEROES-RECOVER, includes more than 4,000 health care workers, first responders, and other frontline workers in eight locations across six states, all of whom have been tested weekly for infection with SARS-CoV-2.

With real-world data in hand, the Institute for Clinical and Economic Review (ICER) is retooling its cost-effectiveness models for three rare disease drugs. And the new discounts it has in mind are steep.

Coronavirus vaccines provided strong protection against infection for essential workers earlier this year, but have become less effective.

The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of mavacamten (MyoKardia and Bristol-Myers Squibb) for the treatment of hypertrophic cardiomyopathy.

Reflecting Poorly: Health Care in the U.S. Compared to Other High-Income Countries

NICE is changing how it assess new drugs, devices, diagnostics and digital technologies to provide faster and fairer access in the NHS. The changes will also improve the way it works with patients, the NHS and the life sciences industry.

Medicare negotiation and inflation rebates would likely have the unintended effect of modestly lowering the rebates manufacturers must now pay state Medicaid programs, thereby raising federal and state Medicaid prescription drug costs.

The pharmaceutical industry has long argued that high drug prices reflect the high cost of innovation and that reducing drug prices would necessarily slow the pipeline of new drugs.

New research shows that drug price reductions under the US’s H.R. 3 policy could have no impact on innovation in the pharmaceutical industry.